A Phase 2 interventional study of EDP-938 and Placebo in Respiratory Syncytial Virus Infections, sponsored by Enanta Pharmaceuticals, Inc. Terminated at 64 sites in 19 countries. Open to participants aged 16 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-22.
Sponsored by Enanta Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections — 1 open to participants now, 1 under way, none of them phase 3. EDP-938 · Respiratory Syncytial Virus Infections.
Among the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections, this one is the 10th largest by enrollment, is one of 2 that started in 2021, is one of 4 in phase 2, and was the 6th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →1 of the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:
Enanta Pharmaceuticals, Inc · Sites in Thailand
Ages 28 days–36 mo
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 16 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 81 across the 10 interventional studies. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 1 most frequent:
Enanta Pharmaceuticals, Inc is the lead sponsor of 46 studies on the registry; 3 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
14 studies in Respiratory Syncytial Virus Infections by Enanta Pharmaceuticals, Inc: 1 open now, 1 under way, none of them phase 3. Of 13 finished, 4 (31%) have results posted.
Among the 14 studies in Respiratory Syncytial Virus Infections by Enanta Pharmaceuticals, Inc, this one is the 14th largest by enrollment, is one of 2 that started in 2021, is one of 5 in phase 2, and was the 6th registered.
Enanta Pharmaceuticals, Inc’s Respiratory Syncytial Virus Infections studies by the year they started, since 2017.
1 of the studies testing EDP-938 in Respiratory Syncytial Virus Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07482657Enanta Pharmaceuticals, IncA Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Enanta Pharmaceuticals, Inc’s 14 in Respiratory Syncytial Virus Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a Phase 2b, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of EDP-938 in HCT recipients with acute RSV infection and symptoms of URTI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: EDP-938
Drug: Placebo
EDP-938 800mg Dose adjustments were made for subjects taking azole antifungals.
Subjects took EDP-938 matching placebo tablets once a day orally for 21 days
Percentage of Subjects Who Develop Lower Respiratory Tract (LRTC) Complication
Time frame: Day 1 through Day 28
Change From Baseline in RSV RNA Viral Load
Time frame: Day 1 through Day 49
Proportion of Subjects Progressing to Respiratory Failure (of Any Cause) Requiring Mechanical Ventilation (Invasive or Noninvasive) or All-cause Mortality
Time frame: Day 1 through Day 49
Safety as Measured the Number of Participants With at Least One Treatment-emergent Adverse Event
Time frame: Day 1 through Day 49
Plasma PK Concentrations of EDP-938 800mg
Time frame: Day 1 Predose and Postdose, Day 4 Predose, Day 7 Predose and Postdose, Day 11 Predose, Day 16 Predose, Day 21 Predose and Postdose
| Milestone | EDP-938 | Placebo |
|---|---|---|
| Started | 5 | 4 |
| Edp-938 150 mg | 1 | 0 |
| Edp-938 400 mg | 1 | 0 |
| Edp-938 800 mg | 3 | 0 |
| Completed | 5 | 4 |
| Not completed | 0 | 0 |
| Participants | EDP-938 | Placebo |
|---|---|---|
| Percentage of Subjects Who Develop Lower Respiratory Tract (LRTC) Complication | 0 | 1 |
| RSV viral load (log10 copies/mL) | EDP-938 | Placebo |
|---|---|---|
| Change From Baseline in RSV RNA Viral Load | -7.072 ± 0.7738 | -2.221 ± 6.8552 |
| Participants | EDP-938 | Placebo |
|---|---|---|
| Proportion of Subjects Progressing to Respiratory Failure (of Any Cause) Requiring Mechanical Ventilation (Invasive or Noninvasive) or All-cause Mortality | 0 | 0 |
| Participants | EDP-938 | Placebo |
|---|---|---|
| Safety as Measured the Number of Participants With at Least One Treatment-emergent Adverse Event | 5 | 3 |
| ng/mL | EDP-938 |
|---|---|
| Day 1 Predose | 0 ± 0 |
| Day 1 Postdose | 1123.33 ± 1028.899 |
| Day 4 Predose | 1610.00 ± 175.784 |
| Day 7 Predose | 1342.33 ± 411.554 |
| Day 7 Postdose | 1394.33 ± 493.504 |
| Day 11 Predose | 1176.67 ± 204.287 |
| Day 16 Predose | 860.00 ± 411.887 |
| Day 21 Predose | 755.33 ± 58.011 |
| Day 21 Postdose | 1136.00 ± 656.195 |
Collected over Adverse event data was collected beginning on Day 1 and concluded at the End-of-Study (EOS) visit on Day 49, 28 days following the last dose of the study drug.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EDP-938 | 0/5 (0%) | 4/5 (80%) | 5/5 (100%) |
| Placebo | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Event | EDP-938 | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/5 | 0/4 |
| HypertransaminasaemiaHepatobiliary disorders | 1/5 | 0/4 |
| Mucosal infectionInfections and infestations | 1/5 | 0/4 |
| Decreased appetiteMetabolism and nutrition disorders | 1/5 | 0/4 |
| Event | EDP-938 | Placebo |
|---|---|---|
| HypokalaemiaMetabolism and nutrition disorders | 2/5 | 0/4 |
| HypomagnesaemiaMetabolism and nutrition disorders | 2/5 | 0/4 |
| NauseaGastrointestinal disorders | 2/5 | 1/4 |
| VomitingGastrointestinal disorders | 2/5 | 1/4 |
| PyrexiaGeneral disorders | 2/5 | 0/4 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/5 | 0/4 |
| ConjunctivitisInfections and infestations | 0/5 | 1/4 |
| FolliculitisInfections and infestations | 0/5 | 1/4 |
| HypervolaemiaMetabolism and nutrition disorders | 0/5 | 1/4 |
| HypocalcaemiaMetabolism and nutrition disorders | 1/5 | 1/4 |
| Age, Continuous(Years) | EDP-938 | Placebo | Total |
|---|---|---|---|
| Mean | 44.4 ± 15.98 | 44.3 ± 15.99 | 44.3 ± 14.95 |
| Sex: Female, Male(Participants) | EDP-938 | Placebo | Total |
|---|---|---|---|
| Female | 2 | 2 | 4 |
| Male | 3 | 2 | 5 |
| Ethnicity (NIH/OMB)(Participants) | EDP-938 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 4 | 4 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | EDP-938 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 5 | 3 | 8 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2021 to primary completion in May 2023, 22 months.
Results were first posted in Aug 2024, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: EDP-938
Respiratory Syncytial Virus Infections →